tabletki o przedłużonym uwalnianiu

DRUG5 trials

Sponsors

Medical University Of Lodz, Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy, Medical University Of Gdansk, The Pharmaceutical Company LEK-AM Sp. Zoo., Przedsiebiorstwo Farmaceutyczne Lek-Am Sp. z o.o., Minoryx Therapeutics S.L.

Conditions

000 people may be affected by HCM3) and all-cause mortality (RR 2.5; 95% CI 1.8-3.4) with a mean follow-up of 7 years. HenceAF occurence is even higherAdrenoleukodystrophyAttention-deficit hyperactivity disorderDuchenne muscular dystrophy; Cardiomyopathy; TachycardiaHCM is likely to affect around 20 million peopleHypertrophic cardiomyopathy (HCM) is the most common genetically determined disease of the heart

Phase 1

A PHASE 1, OPENLABEL, SINGLECENTER STUDY TO EVALUATE DRUGDRUG INTERACTIONS WITH GEMFIBROZIL, ITRACONAZOLE, AND CARBAMAZEPINE AND THE FOOD-EFFECT ON ORAL LERIGLITAZONE IN MALE HEALTHY SUBJECTS

RecruitingCTIS2025-521508-23-00

Minoryx Therapeutics S.L.Adrenoleukodystrophy

Start: 2025-10-10Target: 73Updated: 2025-10-16

Phase 2

LAMAinDiab - lisdexamphetamine vs methylphenidate for pediatric patients with ADHD and type 1 diabetes - a randomized crossover clinical trial.

Active, not recruitingCTIS2023-506862-30-00

Medical University Of LodzAttention-deficit hyperactivity disorder, Type 1 diabetes

Start: 2024-11-24Target: 150Updated: 2025-08-25

Phase 3

The efficacy and safety of Metoprolol as add-on treatment to standard of care in preventing cardiomyopathy in patients with Duchenne Muscular Dystrophy aged 8-17 years. A randomized, double-blind, placebo controlled study

CompletedCTIS2024-515057-19-00

Medical University Of GdanskDuchenne muscular dystrophy; Cardiomyopathy; Tachycardia

Start: 2021-07-12End: 2025-10-06Target: 144Updated: 2024-12-16

A randomized, double-blind, placebo-controlled, multicenter study evaluating the effect of a 12-week DHEA combination of 20 mg and 2 mg prolonged-release melatonin on sleep quality and mood in postmenopausal women.

RecruitingCTIS2024-520234-30-00

The Pharmaceutical Company LEK-AM Sp. Zoo., Przedsiebiorstwo Farmaceutyczne Lek-Am Sp. z o.o.Menopause, sleep disorders in the postmenopausal period

Start: 2024-11-30Target: 100Updated: 2025-05-13

Phase 4

Early ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy

CompletedCTIS2023-508743-43-00

Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy000 people may be affected by HCM, 3) and all-cause mortality (RR 2.5; 95% CI 1.8-3.4) with a mean follow-up of 7 years. Hence, AF occurence is even higher +25

End: 2025-09-16Target: 725Updated: 2024-09-16